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Background: The mechanism of influenza mediated TGF activation, and its role in pathogenesis is unclear.
Results: H1N1 infection induced v6-dependent TGF activity in iHBECs and increased epithelial cell death and collagen
deposition in vivo.
Conclusion: v6 integrin-mediated TGF activation is involved in cell death and fibrogenesis following virus-induced epi-
thelial injury.
Significance: Viral infection may promote acute exacerbations of fibrotic lung disease.
Influenza infection exacerbates chronic pulmonary diseases,
including idiopathic pulmonary fibrosis. A central pathway in
the pathogenesis of idiopathic pulmonary fibrosis is epithelial
injury leading to activation of transforming growth factor 
(TGF). The mechanism and functional consequences of influ-
enza-induced activation of epithelial TGF are unclear. Influ-
enza stimulates toll-like receptor 3 (TLR3), which can increase
RhoA activity, a key event prior to activation of TGF by the
v6 integrin.We hypothesized that influenza would stimulate
TLR3 leading to activation of latent TGF via v6 integrin in
epithelial cells. Using H1152 (IC50 6.1M) to inhibit Rho kinase
and 6.3G9 to inhibit v6 integrins, we demonstrate their
involvement in influenza (A/PR/8/34 H1N1) and poly(I:C)-in-
ducedTGF activation.We confirm the involvement ofTLR3 in
this process using chloroquine (IC50 11.9 M) and a dominant
negative TLR3 construct (pZERO-hTLR3). Examination of
lungs from influenza-infected mice revealed augmented levels
of collagendeposition, phosphorylatedSmad2/3,v6 integrin,
and apoptotic cells. Finally, we demonstrate thatv6 integrin-
mediated TGF activity following influenza infection promotes
epithelial cell death in vitro andenhanced collagendeposition in
vivo and that this response is diminished in Smad3 knock-out
mice.Thesedata show thatH1N1andpoly(I:C) can inducev6
integrin-dependent TGF activity in epithelial cells via stimu-
lation of TLR3 and suggest a novel mechanism by which influ-
enza infectionmay promote collagen deposition in fibrotic lung
disease.
Influenza A is a single-stranded RNA virus that infects the
upper and lower respiratory tract. During seasonal epidemics,
there are an estimated 3–5 million severe cases resulting in
250,000–500,000 deaths worldwide (WHO Media Centre).
This can rise significantly during pandemics. People with
chronic lung disease are more susceptible to influenza infec-
tion, whichmay lead to exacerbation of pre-existing conditions
such as pulmonary fibrosis (1). Although there have been case
histories describing influenza-induced exacerbation of idio-
pathic pulmonary fibrosis, and H5N1may promote pulmonary
fibrosis in mice (2), the mechanisms by which influenza may
promote, or exacerbate, fibrosis are unclear.
A central pathway in the pathogenesis of pulmonary fibrosis
is activation of transforming growth factor  (TGF) in epithe-
lial cells and activation of the downstreamSmad signaling path-
way (3). TGF is a pleiotropic cytokine involved in develop-
ment, inflammation, and wound repair. Aberrant activation of
TGF is implicated in the pathogenesis of chronic lung disease
such as pulmonary fibrosis (4), asthma (5), and emphysema (6).
TGF is secreted noncovalently associated with the latency-
associated peptide (LAP),3 rendering it as an inactive small
latent complex. Association of the small latent complex with
the latent TGF-binding protein (LTBP1–4) forms the large
latent complex, which is tethered to, and sequestered in, the
extracellular matrix. Activation of the latent TGF complex is
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the rate-limiting step in its bioavailability. There are several
known mechanisms of TGF activation, including physical
activation by reactive oxygen species (7) and extremes of pH
and heat (8), proteolytic cleavage by plasmin and tryptase (9),
and by thrombospondin-1 (10). In vivo, however, the main
source of TGF activation involves the engagement of cell-sur-
face integrins (4).
Integrins are heterodimeric cell surface adhesion molecules
composed of  and  subunits. The LAP portion of the latent
TGF complex contains an arginine-glycine-aspartic acid
(RGD) sequence motif that can bind directly to 6 out of 24
described integrins. In this way, four integrins are known to
bind and activate latent TGF as follows: v3, v5, v6,
and v8 (4, 11–13). Mice engineered to express mutant tgfb1
that contains an RGEmotif, instead of RGD, are unable to acti-
vate TGF via integrins. These animals phenocopy the major
abnormalities of TGF1/ mice, suggesting that TGF acti-
vation in vivo is predominantly mediated by integrins (14), at
least during development. The v8 integrin, in association
with matrix metalloproteinase-14 (MMP14), activates TGF
by proteolysis of LAP (13), whereas v3, v5, and v6
integrins activate TGF by a process involving cell traction
(15–17). The v6 integrin is an epithelium-restricted mole-
cule expressed at low levels in the skin and lungs of healthy
individuals and is rapidly up-regulated in response to inflam-
mation and injury (4, 18). Previouswork by this group identified
a mechanism of TGF activation via the v6 integrin involv-
ing stimulation of the GTPase RhoA and its major downstream
effector Rho kinase (15, 19).
Direct activation of latentTGF can occur during incubation
with neuraminidase (NA) in cell-free assays. NA is an influenza
viral coat protein that functions as a sialidase promoting the
release of progeny virus particles from infected cells (20, 21).
NA is able to cleave carbohydrate structures present on theLAP
(22) releasing free TGF, but whether this mechanism of acti-
vation is important in vivo remains unclear. However, alterna-
tivemechanisms of influenza-mediated TGF activation in cell
culture have not been described.
Toll like receptors (TLRs) are components of the innate
immune system that share an intracellular toll-IL-1 receptor
(TIR) cytoplasmic domain. TLRs detect pathogens such as bac-
teria, microbes, and viruses, and 10 TLRs have been identified
inmammals. TLR3 is located on the endosomalmembrane and
recognizes dsRNA, an intermediate product from replicating
RNA viruses such as influenza (23). The synthetic dsRNA ana-
log poly(I:C) can activate RhoA in small airway epithelial cells
(24), raising the possibility that influenza might be able to acti-
vate TGF via TLR3 and cell traction in epithelial cells. There-
fore, we hypothesized that influenza infection of epithelial cells
could activate TGF via TLR3, leading to downstream activa-
tion of RhoA and the v6 integrin.
The results described herein suggest a novel mechanism by
which influenza infection can induce epithelial cell death and
promote collagen deposition, which are critical steps in exacer-
bations of pulmonary fibrosis (25). This further raises the pos-
sibility that TLR3 activation by multiple RNA viruses may
increase TGF activity in epithelial cells and define a mecha-
nism throughwhich viral infectionmay initiate acute exacerba-
tions of fibrotic lung disease.
EXPERIMENTAL PROCEDURES
Cells, Reagents, and Plasmids—Immortalized human bron-
chial epithelial cells (iHBEC), from Jerry Shay (University of
Texas Southwestern, Dallas) (26), were cultured in keratinocyte
serum-free medium (KSFM, Invitrogen) supplemented with
bovine pituitary extract (25 g/ml), epidermal growth factor
(0.2 ng/ml), geneticin (G-418 sulfate, 25 g/ml), and puromy-
cin dihydrochloride (250 ng/ml) and were maintained at 37 °C
in 5% CO2. Madin-Darby canine kidney cells were from ATCC
(Middlesex, UK) and were used for titration of viral stocks.
Transformed mink lung epithelial cells (TMLCs) were a gift
from Daniel Rifkin (New York University, New York). TMLCs
were cultured inDulbecco’smodified Eagle’smedium (DMEM)
supplemented with 10% fetal bovine serum (FBS), geneticin
(G-418 sulfate, 250g/ml), L-glutamine (2mmol/liter), penicil-
lin (100 units/ml), and streptomycin sulfate (100 g/ml). Influ-
enza A low pathogenic virus strain H1N1 A/Puerto Rico/8/34
(PR8) was purchased from the Health Protection Agency Cul-
ture Collections (Salisbury, UK). Mouse-adapted H1N1 influ-
enza A A/FM/1/47-MA virus was kindly provided by Dr. Earl
Brown, University of Ottawa, Ottawa, Canada, and is a fully
sequenced, plaque-purified preparation that is biologically
characterized with respect to mouse lung infections (27).
CAGA12-MLP-Luc (CAGA-box) TGF reporter was a gift
from Caroline Hill (Cancer Research UK, London Research
Institute, London, UK) (28). The dominant negative TLR3-
TIR construct pZERO-hTLR3 was purchased from Source
Bioscience Life Sciences (Nottingham, UK). The empty vector
pcDNA3.1 and the internal transfection controlRenilla lucifer-
ase pRL-SV40 was from Invitrogen and Promega (Southamp-
ton UK), respectively. TransFast transfection reagent (Pro-
mega) was used to transiently transfect iHBECs. Recombinant
TGF1 was from R&D Systems (Abingdon, UK). The v6
integrin function-blocking antibody, clone 6.3G9, was pro-
duced as described (Biogen Idec, Cambridge,MA) (29), and the
pan-TGF antibody, clone 1D11, was from R&D Systems.
Chloroquine, an inhibitor of endosomal acidification, was pur-
chased from Source Bioscience, Lifesciences (Nottingham,
UK). The synthetic double-stranded RNA analog polyinosinic:
polycytidylic acid (poly(I:C)) was purchased from Sigma, and
the Rho kinase inhibitor H-1152 dihydrochloride was from
Tocris Bioscience (Bristol, UK). Phospho-Smad2 (Ser-465/467)
antibody was from Cell Signaling Technology (Danvers, MA).
Anti-collagen I, III, IV, and VI antibodies were from Abcam
(Cambridge, UK). Anti-mouse influenza A nucleoprotein anti-
gen (60 kDa) was from Oxford Biotechnology Ltd. (Oxford,
UK).
Infection of Cells with Influenza A Virus—Cells were grown
until they reached 80–90% confluence and were then growth-
arrested by incubating overnight in serum-free media prior to
the start of all experiments. Cells were treated with influenza A
virus strain H1N1 (A/PR/8/34) at varying multiplicities of
infection (m.o.i.) in serum-free media supplemented with 1
g/ml L-1-tosylamide-2-phenylethyl chloromethyl ketone
(TPCK)-treated trypsin (Sigma) for 1 h at 37 °C. Control cells
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underwent a “mock” infection, following the infection protocol
butwith the omission of influenza virus (TPCK-trypsin 1g/ml
in serum-free media). After the initial infection period, the
virus-containing media was removed, and cells were washed
twice in warm sterile phosphate-buffered saline and were then
incubated with KSFM maintenance media. For experiments
concerned with only one viral replication cycle (0–8 h post-
infection), this consisted of KSFM supplement-free media. In
experiments where multiple viral replication cycles occurred,
the maintenance media consisted of KSFM supplemented with
bovine pituitary extract and EGF (as above) and 0.25 g/ml
TPCK-trypsin. Antibodies and inhibitors were administered as
described in the text.
Flow Cytometry—Flow cytometry was performed to confirm
cell-surface expression of the v and 6 integrin subunits on
iHBECs as described previously (19). Briefly, iHBECs were cul-
tured in 12-well plates; unstimulated cells were harvested, and
nonspecific binding was inhibiting by blocking with goat
serum. Cells were incubated with either a 6-specific primary
antibody (6.3G9) or an v-specific primary antibody (clone
17E6 Abcam), followed by a FITC or PE-conjugated secondary
antibody, and analyzed using a FACScanto II flow cytometer
(BD Biosciences).
Polymerase Chain Reaction—Total cell (including viral) RNA
was extracted using NucleoSpin RNA II kit (Macherey-Nagal,
Fisher), according to the manufacturer’s instructions. Comple-
mentary DNA (cDNA) was made using random primers and
Superscript III (Invitrogen)-reverse transcriptase. PCR was
performed to amplify influenza matrix gene on a Bio-Rad ther-
mocycler using GoTaq Taq polymerase (Promega, Southamp-
ton, UK). The following conditions were used: one cycle of
94 °C for 4 min followed by 29 cycles of 94 °C for 20 s, 58 °C for
30 s, and 72 °C for 2min. The programwas completed with one
cycle of 72 °C for 2min. PCRproducts were run on a 2% agarose
gel in TAE buffer in the presence of ethidium bromide, and
bands were visualized under ultraviolet light on a Syngene
GBox gel documentation system (ImgenTechnologies, Alexan-
dria, VA). Primer sequences are given as follows: hemagglutinin
sense, 5-ACAGCCACAACGGAAAACTATG-3, and hemag-
glutinin antisense, 5-CCGGACCCAAAGCCTCTAC-3;
matrix sense, 5-CCGAGATCGCACAGAGACTTGAAGAT-
3, and matrix antisense, 5-GGCAAGTGCACCAGCAG-
AATAACT-3.
Quantitative Real Time PCR—Total RNA was isolated from
mouse lungs ex vivo using TRIzol (Invitrogen) as described pre-
viously (18). Briefly, one lobe of mouse lung was homogenized
in 1 ml of TRIzol (Invitrogen). Samples were incubated for 5
min at room temperature prior to addition of 200 l of chloro-
form (Sigma). Samples were incubated at room temperature for
3 min prior to centrifugation at 11,000  g for 20 min. The
aqueous phase was removed and incubated with 500 l of iso-
propyl alcohol at room temperature for a further 10 min. Fol-
lowing further centrifugation, RNA samples were washed with
75% ethanol and incubated at 80 °C for 1 h. RNAs were dis-
solved in nuclease-free water, and nucleic acid concentration
was determined. cDNAwas reverse-transcribed usingMoloney
murine leukemia virus from 2 ng of template RNA, and then 2
l of cDNAwas used in a total reaction of 24l for quantitative
PCR analysis. Quantitative RT-PCR analysis was performed
using an MxPro3000P (Stratagene; Agilent Technologies, UK)
on the following program: 3min at 95 °C for 1 cycle; 5 s at 95 °C
followed by 1 min at 60 °C for 45 cycles, and finally 1 min at
95 °C followed by 30 s at 60 °C and 30 s at 95 °C for 1 cycle.
Melting curve analysis was performed to ensure the amplifica-
tion of only one DNA product. Data were analyzed using the
CT method, and the expression of itgb6 was compared with
the expression of hprt1. The primer sequences used are as fol-
lows: murine Itgb6 sense, 5-TCTGAGGATGGAGTGCT-
GTG-3, and murine Itgb6 antisense, 5-GGCACCAATGGC-
TTTACACT-3; murine hprt1 sense, 5-TGAAAGACTTGC-
TGGAGATGTCA-3, and murine hrpt1 antisense, 5-
CCAGCAGGTCAGCAAAGAACT-3.
TMLC TGF Reporter Assay—v6-dependent TGF acti-
vationwas assayed by co-culturing iHBECswithTMLCs,which
express firefly luciferase driven by the TGF-inducible portion
of the plasminogen activator inhibitor-1 (PAI-1) promoter (30).
This assay can determine v6-mediated TGF activation,
which does not lead to active TGF being secreted into the
extracellular fluid and therefore cannot be measured by tradi-
tional antibody-based methods. TMLCs do not express the
v6 integrin but drive the expression of firefly luciferase in
response to stimulation by active TGF. Therefore, an increase
in relative luciferase units that can be inhibited by integrin-
blocking antibodies is indicative of increased v6-mediated
TGF activity (30). IHBECs were grown until confluent in
96-well plates and growth-arrested overnight prior to the start
of all experiments. TMLCs were seeded directly on top of the
iHBECs at a density of 5  105 cells/ml in KSFM supplement-
free media plus or minus relevant antibodies, prior to stimula-
tionwith an appropriate agonist, and incubated for 16 h at 37 °C
and 5% CO2. For experiments involving influenza virus,
iHBECswere infectedwithH1N1 (as above) for 1 h, after which
media were removed, and cells were washed thoroughly prior
to the addition of TMLCs. This ensured the reporter cells were
not exposed to virus at any point in the experiment. Following
incubation for 16 h, cells were lysed using a luciferase assay
reporter kit (Promega), and luciferase activity was measured by
assessing luminescence expressed as relative luciferase units
(Microlumat Plus LB 96V Luminometer, Berthold Technolo-
gies GmbH & Co. KG, Bad Wildbag, Germany).
Generation of Plasmid DNA and Transfection of iHBECs—
Competent DH5 Escherichia coli cells (Invitrogen) were
transformed with plasmid DNA and grown under ampicillin
(CAGA12-Luc, Renilla, pcDNA3.1) or puromycin (pZERO-
hTLR3) selection, and plasmid DNAwas purified using Qiagen
plasmid midi-prep kit (Qiagen, Crawley, UK). The relevant
plasmid DNA was transiently transfected into iHBECs using
TransFast transfection reagent (Promega, UK) according to the
manufacturer’s instructions. Briefly, iHBECs were transfected
with a TGF reporter construct CAGA12-Luc and Renilla;
CAGA12-Luc, Renilla, and TLR3-TIR; or CAGA12-Luc,
Renilla, and the empty vector control pcDNA3.1. After 2 h,
transfection media were removed, and cells were incubated in
serum-free media for 16 h before being stimulated with either
poly(I:C) or H1N1. Co-transfection of cells with Renilla plas-
mid acted as an internal control. Cells were then lysed, and both
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firefly andRenilla luciferase activityweremeasured usingDual-
Luciferase reagent (Promega) and were read on a Berthold
Microlumat Plus LB 96V luminometer. The firefly-to-Renilla
ratio was then calculated.
Phalloidin Staining—Tovisualize themorphological changes of
cells and the actin cytoskeleton in response to H-1152, iHBECs
were stained with phalloidin (Sigma). iHBECs were grown in
chamber slides until they reached 90% confluence and were
then growth-arrested overnight in serum-free medium. Next,
cells were treated with H1152 (10 M) for 30 min prior to stim-
ulation with poly(I:C) (20 g/ml) and were incubated at 37 °C
5% CO2 for 16 h. Prior to staining, cells were washed and fixed
in 4% paraformaldehyde for 10 min, and then washed a further
three times before being washed in PBS containing 0.1% Triton
X-100. Cells were then stained with 50 g/ml fluorescent con-
jugated phalloidin with DAPI (1g/ml) to counterstain the cell
nuclei for 30 min. Cells were washed, mounted, and visualized
by confocal microscopy (Ti Eclipse A1 Confocal, Nikon, Rich-
mond, UK).
Annexin VAssay—iHBECsweremock- or influenza-infected
and incubated with or without an v6 integrin-blocking anti-
body (6.3G9) or a pan-TGF blocking antibody (1D11) for 48 h.
TGF (500 pg/ml) acted as a positive control. Cells were then
stainedwith annexinV andpropidium iodide using an annexin-
V-FITC apoptosis detection kit according to the manufac-
turer’s instructions (Sigma). Quantification was performed
using a BD FACSCanto II flow cytometer and the proportion of
live (no staining), apoptotic (annexin V staining), and necrotic
(annexin V and/or propidium iodide) cells was determined.
Immunohistochemistry—Five-m-thick lung tissue sections
from x31-infected mice were cut from paraffin-embedded lung
tissue sections. Sections were deparaffinized in xylene and
rehydrated in graded ethanol. Antigen retrieval was performed
via proteolytic digestion with pepsin for 15 min at 37 °C (v6
integrin and phospho-Smad2) or by placing sections in 10 mM
sodium citrate buffer and heating in a microwave for 10 min.
Next, endogenous peroxidase was blocked by incubating for 30
min in 3%H2O2 inmethanol. Endogenous avidin/biotin activity
was blocked using an avidin/biotin blocking kit (Vector Labo-
ratories, Peterborough, UK) for influenza A virus-stained sec-
tions only. Nonspecific antibody binding was blocked using
goat serum for 30 min, prior to incubation with human/mouse
chimeric anti-v6 (ch2A1) (0.5 g/ml) (31) phosphorylated
Smad2/3, anti-influenza A (13.3 g/ml), collagen I (2 g/ml),
III (1 g/ml), IV (0.5 g/ml), or VI (0.5 g/ml) primary anti-
body overnight at 4 °C. Sections were then incubated with a
biotin-conjugated secondary antibody. Influenza A virus was
detected using a VectorM.O.M.TM Immunodetection kit (Vec-
tor Laboratories, Peterborough, UK). Briefly, sections were
incubated for 1 h in M.O.M.TM mouse Ig blocking reagent.
Sections were then incubated with anti-influenza A primary
antibody overnight at 4 °C. Sections were then incubated in
M.O.M.TM biotinylated anti-mouse IgG reagent for 10 min.
Biotin-conjugated secondary antibody was detected, in all sec-
tions, through incubation with an avidin/biotinylated enzyme
complex (ABC) solution (Vector Laboratories) for 30min; color
development was performed using 3,3-diaminobenzidine tet-
rahydrochloride (Sigma). Sections were counterstained using
Mayer’s hematoxylin and visualized under a Nikon 90i light
microscope.
Masson Trichrome Staining—Collagen fibers in tissue sec-
tions from x31 and control infected mice were visualized by
Masson Trichrome staining, as described previously (19).
Briefly, 5-m-thick lung tissue sections were deparaffinized in
xylene and rehydrated in graded ethanol. Sections were then
mordant inBouin’s solution (Sigma) overnight at room temper-
ature before being rinsed in water and stained with working
Weigert’s iron hematoxylin (Sigma) for 5 min. After a further
rinse, sections were stained with Biebrich scarlet-acid fuchsin
solution (Sigma) for 5 min before being rinsed again. Sections
were then placed in phosphomolybdic/phosphotungstic acid
solution (Sigma) for 5 min and were then stained with aniline
blue (Sigma) for 5 min. After a further wash, sections were
placed in a 1% (v/v) acetic acid solution for 5min, dehydrated to
xylene, and mounted. Sections were visualized using a Nikon
90i light microscope.
Detection of Apoptosis in Vivo—Fragmentation of nuclear
DNA in tissue sections from x31- and sham-infected mice was
visualized using TACSXL in situ apoptosis detection kit (R&D
Systems), according to the manufacturer’s instructions. Sec-
tions were counterstained with nuclear fast red and visualized
under a Nikon 90i light microscope.
Murine Influenza Infection—Two viral infections were per-
formed in mice using either x31 (a reassortment virus consist-
ing of the viral coat proteins fromH3N2 and the internal genes
from H1N1/PR8 strain) or A/FM/1/47-MA (a mouse-adapted
H1N1 influenza virus). All animal experiments using x31 were
approved by the University of Nottingham Ethical Review
Committee and performed in the Biomedical Services Unit at
the University of Nottingham under Home Office Project and
Personal License Authority within the Animal (Scientific Pro-
cedures) Act 1986. C57BL/6micewere purchased fromCharles
River UK and housed in groups of up to five per cage, with free
access to food and water (Tekland Global 18% protein rodent
diet; Bicester, Oxen, UK). Mice were injected with either an
anti-v6 integrin blocking antibody (6.3G9; 1mg/kg in 200l
of saline intraperitoneal, Biogen Idec) or an isotype control
antibody (1E6; 1 mg/kg in 200 l saline intraperitoneal, Biogen
Idec). One hour later mice were anesthetized using isoflurane
and infected with x31 (50 HA in 50 saline i.n. or saline only (50
l i.n.)). Animals were thenmonitored and weighed every 24 h.
Administration of antibody was repeated on days 2 and 4 (as
above). Animals were euthanized on day 5, and the lungs were
snap-frozen for further analysis. To investigate changes in
Smad2/3 phosphorylation andv6 expression over time,mice
were infected with influenza x31 as described and euthanized 3
or 7 days later. The lungs were removed; one lobe was homog-
enized immediately in 1 ml of RDL lysis buffer containing sup-
plements for 1 min for protein analysis before being snap-fro-
zen in liquid nitrogen. The rest of the lung set was snap-frozen
and stored at80 °C for mRNA analysis.
All experiments using A/FM/1/47-MA were performed at
McMaster University and subject to ethical review by the
McMaster University Animal Research Ethics Board. Smad3/
mice on a 129SV/EV  C57BL/6 background were generated
by deletion of exon eight of the Smad3 gene by Yang et al. (32).
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Mice were bred in-house and genotyped as described previ-
ously (33). Smad3/ mice and littermate controls were anes-
thetized using isoflurane and infected intranasally with either
50 pfu of influenza A/FM/1/47 in 35 l of PBS or a vehicle
control. Animals were monitored, weighed daily, and eutha-
nized at 5 days post-infection. Lungs were snap-frozen for
analysis.
Immunoblotting—Mouse lungs were harvested and immedi-
ately homogenized in 1 ml of protein lysis buffer containing
Tris-HCl, pH 7.4 (20mM),NaCl (137 nM), EDTA (2 nM),-glyc-
erophosphate (25 mM), Na3VO4 (1 nM), 1% Triton X-100, 10%
glycerol, and distilled H2O. This buffer was supplemented with
leupeptin, phenylmethylsulfonyl fluoride (PMSF), protease
inhibitor (protease inhibitor mixture, Roche Applied Science),
dithiothreitol (DTT), and phosphatase inhibitor (PhosStop,
Roche Applied Science). Samples were then stored at 80 °C
until further use. Protein concentration of sampleswas assessed
using a Pierce bicinchoninic acid (BCA) colorimetric assay kit
(Fisher), according to the manufacturer’s instructions. Equiva-
lent amounts of protein (100g) were added to Laemmli buffer
containing -mercaptoethanol and loaded onto a 10% bis/ac-
rylamide (w/v) gel. Electrophoresiswas performed for 1 h at 150
V. Protein was transferred onto a polyvinylidene fluoride
(PVDF) membrane using a Criterion blotting system (Bio-Rad)
run at 110 V for 40min.Membranes were incubated for 30min
at room temperature in 10% w/v nonfat dry milk/Tris-buffered
saline Tween 20 (TBST) prior to overnight incubation with pri-
mary antibody diluted with 5% w/v nonfat dry milk/TBST at
4 °C. Membranes were then incubated with the corresponding
HRP-conjugated secondary antibody (0.8 g/ml with 5% w/v
nonfat dry milk/TBST) for 1 h at room temperature, and pro-
tein was visualized on hyperfilm using enhanced chemilumi-
nescence detection reagent (Bio-Rad).
Hydroxyproline Assay—Lung homogenates were placed in
glass tubes and incubated with 125 l of 50% trichloroacetic
acid (Sigma) on ice for 20min. Samples were centrifuged for 10
min following which the supernatants were removed and dis-
posed. One milliliter of 12 N HCl was then added to each tube,
and samples were incubated overnight at 110 °C until all liquid
had evaporated. Samples were then dissolved in water, incu-
bated with chloramine T (Sigma) for 20min, followed by a final
incubationwith 500l of Ehrlich’s solution (Fisher) at 65 °C for
15 min. Once samples had cooled to room temperature, 100 l
from each tubewas transferred to a 96-well plate; absorbance at
550 nm was determined, and the level of hydroxyproline/lung
set (total lung collected from animal) was calculated against a
standard curve.
Determination of Viral Load in Lungs from Influenza-infected
Mice—Viral load was calculated using the tissue culture infec-
tive dose (TCID50)method as described previously (21). Briefly,
lungs were homogenized in 1 ml of PBS, clarified by centrifu-
gation, and log dilutions were prepared in minimum Eagle’s
medium containing 0.075% BSA, antibiotics, and 1 g/ml
TPCK-trypsin. Madin-Darby canine kidney cells grown to
80% confluence were infected with the lung dilutions in trip-
licate and incubated at 37 °C and 5% CO2 for 72 h and were
checked daily for cytopathic effect. After 72 h, a hemagglutinin
assay (HA) was performed with 0.5% turkey red blood cells as
described previously (34). The Reed-Muenchmethod was then
used for quantification (35).
Statistical Analysis—All in vitro experiments were per-
formed three times, and data are expressed as themean of three
experiments  S.E. unless otherwise stated. Comparison of
data sets was achieved using unpaired, two-tailed Student’s t
test and was performed using Microsoft Excel. Grouped analy-
sis was performed by two-way analysis of variance using
GraphPad Prism (version 6). Differences were considered sta-
tistically significant at p	 0.05.
RESULTS
H1N1 Influenza A Is Able to Infect Human Bronchial Epithe-
lial Cells Independently of TGFActivity or thev6 Integrin—
To confirm cell-surface expression of the v and 6 integrin
subunits, flow cytometry was performed on unstimulated
iHBECs. These analyses revealed that both subunits of thev6
integrinwere present basally on iHBECs (Fig. 1A). iHBECswere
incubated with influenza A virus H1N1 (PR8, m.o.i. 1) for 1 h.
Total cell RNA was isolated 0–4 h following infection, and the
presence of viral genes was assayed by PCR. Influenza hemag-
glutinin (HA) and matrix gene expression were visible in all
infected samples at all time points. In mock-infected control
cells, no viral mRNAwas detected at any time point. Inhibiting
TGF with a pan-TGF blocking antibody did not affect the
expression of viral genes at any time point assessed. Although
blocking the v6 integrin did not inhibit infection of iHBECs,
there appeared to be reduced expression of viral genes at later
time points (Fig. 1B).
Influenza A Infection Activates Latent TGF via the v6
Integrin in iHBECs—To determine whether influenza virus is
able to activate latent TGF in bronchial epithelial cells,
iHBECs were infected with influenza A H1N1 (PR8, m.o.i. 1),
and TGF activity was assessed. Initially, iHBECswere infected
with H1N1 for 1 h prior to co-culture with TMLCs (a TGF
reporter cell line).
To reduce confounding effects of influenza infection on the
reporter cells, viralmedia were removed prior to the addition of
TMLCs to the co-culture. H1N1 infection increased luciferase
activity (Fig. 1C), which was reduced in cells pretreated with an
v6 integrin blocking antibody (6.3G9), a pan-TGF blocking
antibody (1D11), or a Rho kinase inhibitor (H1152; Fig. 1C).
The increase in luciferase activity was equivalent to 25–50
pg/ml, similar to levels previously observed in primary epithe-
lial cells (15). To confirm influenza infection induced TGF
directly in iHBECs, rather than through indirect effects on
TMLCs, iHBECs were transfected with a TGF-responsive
CAGA12-Luc reporter construct. When infected with H1N1, a
significant increase in the firefly-to-Renilla (F:R) ratio was gen-
erated when compared with mock-infected controls at 4 h
post-infection (Fig. 1D). Thiswas the time point at whichH1N1
infection generated the largest increase in F:R ratio versusmock
infection in pilot studies (data not shown). Collectively, these
data show that influenza virus infection activates TGF in an
v6 integrin-dependent manner in iHBECs.
Poly(I:C), but Not Neuraminidase, Can Activate TGF in
HBECs—To investigate the potential mechanisms through
which influenza infection activates TGF in iHBECs, cells were
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stimulated with poly(I:C), a synthetic dsRNA analog and ligand
for TLR3 or recombinant neuraminidase (NA) from Clostrid-
ium perfringens. Stimulation of iHBECs, in co-culture with
TMLCs, with increasing concentrations of poly(I:C) (0–20
g/ml) induced significant concentration-dependent increases
in luciferase activity (Fig. 2A) that were inhibited with a pan-
TGF-blocking antibody (1D11) and an v6 integrin-block-
ing antibody (6.3G9). To confirm that poly(I:C)-induced TGF
FIGURE1. InfluenzaH1N1activatesTGFvia thev6 integrin inhumanbronchial epithelial cells.A,unstimulated iHBECswere incubatedwith either an
anti-v or an anti-6 antibody and analyzed by flow cytometry. The data reveal that both the v and 6 subunits (solid black lines) are expressed basally on
iHBECs. The dashed lines represent the secondary antibody controls. B, confirmation of influenza A infection in iHBECs. IHBECs were infected with H1N1
(A/PR/8/34) atm.o.i. of 1 for up to 4h, and total RNAwas isolated. Viralmatrix (Mx) andhemagglutinin (HA) genesweredetectedbyPCR in all influenza-infected
but not in mock-infected samples. The experiment was repeated three times, and a representative example is shown. C, iHBECs were pretreated with H1N1
(m.o.i. 1)
 1 g/ml TPCK-trypsin or mock-infected with 1 g/ml TPCK-trypsin only and co-cultured with TMLCs without inhibitors (black bars) and with the
pan-TGF-neutralizing antibody 1D11 (10 g/ml; gray bars), the v6 integrin-blocking antibody 6.3G9 (15 g/ml; striped bars), or the Rho kinase inhibitor
H1152 (10M;white bars). Experiments were performed in duplicate and repeated three times. Themean fold change in total luciferase units compared with
control (mock-infectedwithout inhibitors) of the independent experiments was determined. Data are expressed asmean S.E. ***, p	 0.001.D, iHBECswere
transiently transfected with the TGF-sensitive promoter reporter construct CAGA12-MLP-Luc and Renilla luciferase pRL-SV40, prior to stimulation with 1
g/ml TPCK-trypsin only (mock-infected) or H1N1m.o.i. 1
 1g/ml TPCK-trypsin and incubated for 4 h post-infection (hpi). Experiments were performed in
duplicate and repeated three times. The mean fold change in the F:R ratio versus control (mock-infected) of the independent experiments was determined.
Data are expressed as mean S.E. **, p	 0.01.
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activation was due to a direct effect on iHBECs, cells were tran-
siently transfected with the TGF-responsive CAGA-box
reporter and stimulated with 20g/ml poly(I:C), which led to a
significant increase in reporter activity (Fig. 2B). Although NA
stimulation of iHBECs in co-culture with TMLCs appeared to
induce TGF activity, the effect was not concentration-depen-
dent (Fig. 2C). Furthermore, NA did not significantly increase
luciferase activity from the transiently transfected CAGA-box
reporter (Fig. 2D), suggesting that NA does not mediate influ-
enza-induced TGF activity in this system.
Influenza and Poly(I:C)-mediated TGF Activation Involves
TLR3 and Rho Kinase—To investigate whether endosomal
receptors are involved in dsRNA-mediated TGF activation,
chloroquine, an inhibitor of endosomal acidification, was used.
Poly(I:C)-mediated TGF activity was inhibited by increasing
concentrations of chloroquinewith an IC50 of 11.9M (Fig. 3A).
To confirm that H1N1 influenza infection and poly(I:C) acti-
vate TGF via the endosomal receptor TLR3, cells were co-
transfectedwith a dominant negative construct encodingTLR3
with a deleted TIR domain rendering it inactive (TLR3-TIR)
and the TGF-sensitive CAGA-box reporter construct. Both
poly(I:C) and H1N1 influenza infection were able to stimulate
luciferase activity from the CAGA box reporter-transfected
iHBECs (Fig. 3, B and C). Furthermore, co-transfection of the
dominant negative TLR3 construct completely inhibited both
poly(I:C) and influenza-induced TGF activation as measured by
luciferase activity (Fig. 3,B andC, respectively). Transfectionwith
the dominant negative TLR3-TIR construct had no effect on the
reporter activity of the CAGA-box construct (data not shown).
To determine whether TLR3-mediated activation of TGF
in epithelial cells required Rho kinase as observed with GPCR-
mediated TGF activation (15, 19), iHBECs were treated with a
Rho kinase inhibitor, H1152, prior to stimulationwith poly(I:C)
(20 g/ml). Poly(I:C) induced TGF activation in iHBECs, as
measured by TMLC co-culture assay, was inhibited by H1152
in a concentration-dependent manner (Fig. 3D; IC50  6.815
M) with almost 100% inhibition at the highest dose of 100 M.
The inhibition of TGF activity was not due to an increase in
cell death as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide assay, apart from at the highest
concentration of H1152 used (100 M; data not shown). This
IC50 is of an order of magnitude similar to levels of ROCK
inhibition observed in NT2 cells following lysophosphatidic
acid stimulation (IC50 2.5 M) (36).
FIGURE 2. Poly(I:C) but not NA activates TGF in humanbronchial epithelial cells. A, iHBECswere co-culturedwith TMLCs and stimulatedwith poly(I:C) (0,
10, 15, or 20 g/ml) without inhibitors (black bars) and with either the pan-TGF-neutralizing antibody 1D11 (10 g/ml; gray bars) or the v6-blocking
antibody 6.3G9 (15 g/ml; white bars). Experiments were performed in duplicate and repeated three times. The mean fold change in total luciferase units
compared with control (mock- infected without inhibitors) of the independent experiments was determined. Data are expressed as mean S.E. p	 0.0001
between treatment groups and stimulation versus control. B, iHBECs were transiently transfected with the TGF-sensitive promoter reporter construct
CAGA12-MLP-Luc and Renilla luciferase pRL-SV40 prior to stimulation with 20 g/ml poly(I:C) for 6 h. Experiments were performed in duplicate and repeated
three times. The mean fold change in the F:R ratio versus control (mock-infected) of the independent experiments was determined. Data are expressed as
mean S.E. **, p	 0.01. C, iHBECswere co-culturedwith TMLCs and stimulatedwith increasing concentrations of recombinant NA (0, 0.1, 1, 10, and 100 units)
with (white bars) andwithout (black bars) the pan-TGF-neutralizing antibody 1D11 (10g/ml). Experiments were performed in duplicate and repeated three
times. The mean fold change in total luciferase units compared with control (mock-infected without inhibitors) of the independent experiments was deter-
mined. Data are expressed asmean S.E. p	 0.0001between treatment groups; no effect of stimulation versus control.D, iHBECswere transiently transfected
with the TGF-sensitive promoter reporter construct CAGA12-MLP-Luc, and Renilla luciferase pRL-SV40 prior to stimulation with increasing concentrations of
NA (0–100 units) for 6 h. Experiments were performed in duplicate and repeated three times. The mean fold change in the F:R ratio versus control (mock-
infected) of the independent experiments was determined. Data are expressed as mean S.E.
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To visualize cell morphology in response to ROCK inhibi-
tion, iHBECs were stimulated with poly(I:C) with, or without
H1152, stained with phalloidin and compared with unstimu-
lated cells (Fig. 3E). Confocal microscopy revealed that
poly(I:C) treatment induced stress fiber formation (Fig. 3E,
panel i), consistent with the known mechanisms of TGF acti-
vation (19). Stress fibers were less apparent in control cells (Fig.
3E, panel ii) and were not present in cells treated with H1152
alone (Fig. 3E, panel iii) or in the poly(I:C)-treated cells follow-
ing pretreatment with H1152 (Fig. 3E, panel iv). Furthermore,
morphology of cells treated with H1152 was similar to that of
the control (untreated) cells, suggesting that, at the concentra-
tion used, this inhibitor was not reducing TGF activity
through nonspecific effects on epithelial cells.
Influenza Virus Causes Epithelial Cell Death via TGF and
v6 Integrin—To determine the functional significance of
increased TGF activity during influenza infection, we investi-
gated whether v6 integrin-mediated TGF activation is
involved in H1N1-induced epithelial cell death. When cells
were infectedwith high doseH1N1 (m.o.i. 10), therewas almost
100% cell death, thus precluding analysis of cells by flow cytom-
etry; however, H1N1-induced cell death was not observed in
FIGURE 3. Influenza H1N1 and poly(I:C) activate TGF via stimulation of toll-like receptor 3 and Rho kinase in human bronchial epithelial cells. A,
iHBECs were pretreated with increasing concentrations of chloroquine (0.1–100 M) prior to co-culture with TMLCs and then stimulated with poly(I:C) (20
g/ml) in the presence (black bars) and absence (white bars) of the pan-TGF-neutralizing antibody 1D11. Experiments were performed in duplicate and
repeated three times. Themean fold change in total luciferaseunits comparedwithpoly(I:C)-stimulatedco-cultureswithout chloroquinewasdetermined.Data
are expressed asmean S.E. p	 0.0001 between both treatment groups and stimulation versus control. B, iHBECs were co-transfected with a TGF-sensitive
reporter construct and either dnTLR3-TIR or an empty vector control plasmid and Renilla. Cells were stimulatedwith poly(I:C) (0 or 20g/ml;white and black
bars, respectively) and incubated for 6 h. Experiments were performed in duplicate and repeated three times. The mean fold change in the F:R ratio versus
control (mock-infected) of the independent experiments was determined. Data are expressed as mean S.E. **, p	 0.01. C, iHBECs were co-transfected with
aTGF-sensitive reporter construct andeither dnTLR3-TIRor anempty vector control andRenilla. Cellsweremock-infected (1g/ml TPCK-trypsin;white bars)
or influenza-infected (m.o.i. 1 
 1 g/ml TPCK-trypsin; black bars), and luciferase activity was determined. Experiments were performed in duplicate and
repeated three times. The mean fold change in the F:R ratio versus control (mock-infected) of the independent experiments was determined. Data are
expressed asmean S.E. *,p	0.05.D, iHBECswerepretreatedwith increasing concentrations of theRhokinase inhibitorH1152 (0, 0.1, 1, 10, and100M)prior
to co-culturewith TMLCs and stimulationwith poly(I:C) (20g/ml) in the presence (black bars) and absence (white bars) of the pan-TGF-neutralizing antibody
1D11. Experiments were performed in duplicate and repeated three times. Themean fold change in total luciferase units compared with poly(I:C)-stimulated
co-cultures without H1152 was determined. Data are expressed as mean S.E. p	 0.0001 between both treatment groups and stimulation versus control. E,
iHBECs were stimulated with poly(I:C) for 16 h (panel i), compared with unstimulated iHBEC controls (20 g/ml) (panel ii), iHBECs cultured in the presence of
H1152 (10M) (panel iii), or stimulatedwith poly(I:C) (20g/ml) in the presence of H1152 (10M) and stainedwith FITC-phalloidin to visualize cellmorphology
and the actin cytoskeleton and DAPI to visualize the nucleus (panel iv).White arrows indicate stress fibers.
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cells incubated with either an v6 integrin blocking antibody
or a TGF-blocking antibody (data not shown). When cells
were infected with a lower dose of H1N1, (m.o.i. 2), cell death
was still observed after 48 h (Fig. 4, A and G) compared with
control (Fig. 4, B and G) and TPCK-trypsin treated mock-in-
fected cells (Fig. 4, C and G). Similarly, 48 h of treatment with
TGF (500 pg/ml) also led to increased epithelial cell death
(Fig. 4, D and G). When H1N1-infected iHBECs were pre-
treated with the v6 integrin-blocking antibody, 6.3G9, cell
death was reduced to control levels (Fig. 4, E and G). Blocking
the v6 integrin had no effect on basal rates of iHBEC death
(Fig. 4, F and G). These data suggest that influenza-mediated
TGF activation promotes epithelial cell death via an v6
integrin-dependent pathway.
Influenza Virus Increases Collagen Deposition, TGF Activ-
ity, and Levels of Detectable v6 Integrin in Vivo—Lungs from
sham-infected mice (Fig. 5A, panels i, iv, vii, x, and xiii) were
compared with lungs from x31-infected mice by histology 3
days (Fig. 5A, panels ii, v, viii, xi, and xiv) and 7 days (Fig. 5A,
panels iii, vi, ix, xii, and xv) after infection.Masson’s Trichrome
staining revealed matrix deposition predominantly around the
airways of sham-infected mice (Fig. 5A, panel i). Cellular infil-
tration was observed in the lungs 3 days after infection without
much matrix deposition (Fig. 5A, panel ii). However, 7 days
following infection, there was considerable parenchymal
matrix deposition throughout the pulmonary parenchyma (Fig.
5A, panels ii). Pulmonary infection was confirmed at each time
point by immunostaining with an anti-influenza A nucleoprotein
(60 kDa) antibody (Fig. 5A, panels iv–vi). v6 integrin immuno-
staining was not detected in any cell type in uninfected lungs (Fig.
5A, panel vii). However, the level of positive immunostaining for
v6 integrin increased in the lungs of influenza-infectedmice at
day 3 (Fig. 5A, panel viii) and day 7 post-infection (Fig. 5A, panel
ix). Phosphorylated Smad2/3 immunostaining was widespread
throughout the lungs and was observed in both structural and
inflammatory cells prior to and following influenza infection
(Fig. 5A, panels x–xii). Influenza infection of epithelial cells in
vitro promotes apoptosis (Fig. 4); therefore, sections of lung
were assessed for apoptosis by TUNEL staining. Apoptosis was
not observed in sham-infected lung sections (Fig. 5A, panel
xiii). Interestingly, TUNEL staining was only evident 3 days
after influenza infection (Fig. 5A, panel xiv), whereas at 7 days
following infection (Fig. 5A, panel xv), levels of TUNEL staining
were similar to those observed in sham-infected lungs.
To determine whether global levels of v6 integrin and
phosphorylated Smad2 were increased in the lungs during
influenza infection in vivo, RNA and protein were isolated from
the lungs of x31-infected mice. Three days following influenza
infection, there was an increase in itgb6 expression relative to
that detected in sham-infected mice (Fig. 5B); however, this
increase was not sustained at 7 days. Western blot analysis
revealed that levels of both total and phospho-Smad2 were
increased 3 and 7 days following infection compared with
sham-infected mice (Fig. 5C).
Influenza Infection Causes Increased Lung Collagen Deposi-
tion That Is Dependent on Active TGF Signaling—Infection of
mice with the mouse-adapted influenza strain x31 led to sys-
temic illness characterized by weight loss that was not affected
by administration of an anti-v6 integrin-blocking antibody
(Fig. 6A). Immunohistochemical analysis of lung tissue revealed
the presence of viral proteins at day 5, confirming the presence
of pulmonary infection (Fig. 6B). Influenza infection ofmice led
to increased total lung collagen deposition, asmeasured by bio-
chemical analysis of hydroxyproline levels 5 days post-infection
compared with sham-infected mice (Fig. 6C). This increase in
total lung collagen was inhibited by administration of the anti-
v6 integrin-blocking antibody 6.3G9 and was not affected
following treatment with an isotype control antibody (Fig. 6C).
Blocking the function of the v6 integrin during influenza
infection did not result in any adverse effects compared with
those observed following administration of the isotype control
antibody, andTCID50 analysis of lung homogenates from influ-
enza-infectedmice revealed that therewas no difference in viral
titer between the infected groups (Fig. 6D). Therefore, the
reduced total lung collagen deposition observed was not due to
reduced levels of influenza virus within the lungs. To determine
which collagen subtypes were increased following influenza
infection, lung tissue was examined by immunohistochemistry.
Infection of C57Bl/6 mice with x31 led to a substantial increase
in collagens I, IV, and VI (Figs. 6E, panels i, iii, iv, v, vii, and viii,
and 7) and a smaller increase in collagen III (Figs. 6E, panels ii
and vi, and. 7). Treatment with the anti-v6 integrin-blocking
antibody 6.3G9 led to reduced expression of all collagen sub-
types (Fig. 6E, panels ix–xii).
Infection of mice with the mouse-adapted influenza strain
A/FM/1/47-MA did not affect body weight (Fig. 8A). However,
infection was confirmed by immunohistochemical staining of
the lung (Fig. 8B). Infection with A/FM/1/47-MA also resulted
in a significant increase in lung collagen levels as measured by
hydroxyproline analysis 5 days following infection (Fig. 8C).
However, this increase was not observed in Smad3/ mice
following influenza infection. Analysis of viral titer within the
lung (Fig. 8D) revealed no difference in viral load between wild-
type and Smad3/ mice. This suggests that the reduction in
lung collagen was not due to differences in viral infection
between the wild-type and Smad3/ mice. Analysis of lung
collagens by immunohistochemistry revealed a modest rise in
collagens I, IV, and VI and very little change in collagen III
deposition (Figs. 8E, panels i–viii, and 9). Although there was
no apparent reduction in global collagen staining throughout
FIGURE 4. InfluenzaH1N1-mediated TGF activity induces cell death in humanbronchial epithelial cells. iHBECswere assessed for apoptotic or necrotic
cell death by staining with annexin V (FITC) and propidium iodide (PE) and analyzed via flow cytometry. Cells in Q1 were FITC/PE
 signifying necrosis. In Q2
cellswere FITC
/PE
 and represent those in late apoptosis. Cells in early apoptosiswere inQ3and stained FITC
/PEwhereas those inQ4were FITC/PE and
represented a healthy population. Cells infectedwith influenza atm.o.i. 2 are shown inA comparedwith untreated cells inmedia alone (B),mock infectionwith
media containing TPCK-trypsin (C), and cells stimulatedwith 500 pg/ml TGF (D). Cells infectedwith influenza atm.o.i. 2 in the presence of thev6-blocking
antibody 6.3G9 are shown in E andmock infectionwith TPCK-trypsin in the presence of thev6-blocking antibody 6.3G9 (F). The percentages of cells in each
quadrant are recorded in the respectivequadrants.G,graphical representationof theproportionof cells in eachquadrantunder eachcondition.White,healthy;
light gray, early apoptosis; dark gray, late apoptosis, and black, necrotic.
H1N1 Activates TGF via TLR3 andv6 Integrin
DECEMBER 19, 2014•VOLUME 289•NUMBER 51 JOURNAL OF BIOLOGICAL CHEMISTRY 35255
 by guest on N
ovem
ber 19, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the lung in Smad3/ mice (Fig. 9), high power microscopy
suggested that expression of collagens I, IV, andVI in the alveoli
were reduced in Smad3/mice (Fig. 8E, panels ix–xii).
DISCUSSION
We demonstrate that the functional consequence of increased
v6 integrin-mediated TGF activity during influenza infec-
tion is epithelial cell apoptosis leading to enhanced collagen
deposition through activation of TGF and fibrogenesis in vivo
as early as 5 days post-infection. Furthermore, we describe a
novel mechanism through which influenza infection and a syn-
thetic dsRNA analog activate latent TGF via the innate
immune system receptor TLR3 and activation of the v6
integrin in human bronchial epithelial cells. Furthermore, we
FIGURE 5. Influenza A increases TGF activity,v6 integrin expression, aswell as apoptosis in the lungs of infectedmice.A,micewere sham-infected (A,
panels i, iv, vii, x,andxiii)or infectedwithmurine-adapted influenzavirus (x31,50HAUinsaline i.n.) andeuthanizedthree (A,panels ii, v, viii, xi,andxiv)or seven (A,panels
iii, vi, ix, xii, and xv) days later. Masson’s trichrome staining was performed on lung sections (A, panels i–iii) to examine matrix deposition. Influenza A nucleoprotein
immunostainingwas absent in sham-infected lung sections (A, panel iv), although itwas increased inmice infectedwith influenzaA at day 3 (A, panel v) andday 7 (A,
panelvi). Lungsectionswere immunostainedtoexaminev6 integrinandphosphorylatedSmad2/3expressionandcounterstainedwithhematoxylin.Therewasno
evidenceofv6 immunostaining inuninfectedmice (A, panel vii), but immunostaining increased in thealveolar epitheliumatdays 3 and7 (A, panels viii–ix). Nuclear
stainingofphosphorylatedSmad2/3wasevident inuninfectedmice lungs(A,panelx), andincreasedfollowinginfectionatbothday3(Axi)andday7(A,panelxii). Lung
sectionswere subject to terminal deoxynucleotidyltransferase dUTPnick end labeling staining, and counterstainedwith eosin, to identify dead cells. Dead cellswere
notapparent incontrolsections(A,panelxiii)butwerewidespreadinsectionsfromx31-infectedmiceanalyzedatday3(A,panelxiv)butnotatday7(A,panelxv).B, lung
homogenates from mice infected with murine adapted influenza (x31, 50 HAU in saline i.n.) were analyzed at days 3 and 7 for levels of itgb6 mRNA. C, lung
homogenates frommice infectedwithmurine-adapted influenza (x31, 50HAU in saline i.n.)wereanalyzedatdays3and7 forphosphorylatedand total Smad2 levels.
Smad2was assessed in five animals, and a representativeWestern blot is shown.
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show that TLR3-induced v6 integrin-mediated TGF acti-
vation involves Rho kinase, which is similar to the mechanism
of GPCR-mediated TGF activation (15, 19).
Thev6 integrin acts as a receptor for epithelial cell entry of
the picornavirus Foot-and-Mouth disease in cattle (37, 38),
coxsackievirus A9 in humans (39), and human parechovirus
(40). Similarly, fusion of the herpesvirus Epstein-Barr with epi-
thelial cells has been shown to involvev6 aswell asv5, and
v8 integrins (41–43). However, a similar role for the v6
integrin during influenza infection has not been addressed.Our
data demonstrate that inhibiting the function of v6 integrin
does not alter the cellular uptake of influenza virus in epithelial
cells. Furthermore, in contrast with the picornavirus coat pro-
teins (39), neither of the influenza coat proteins NA or HA
contain an RGD sequence, which is required for interaction
with TGF-activating integrins. Interestingly, both influenza
polymerase basic proteins 1 and 2 (PB1–2) contain an RGD
sequence, which is conserved across all influenza strains. This
suggests that although the v6 integrin is not involved in epi-
thelial cell internalization of influenza virus, it could be
involved in viral replication. However, as no difference in viral
load was found in the lungs of mice treated with an anti-v6
FIGURE 6. Influenza A leads to enhanced collagen deposition that is dependent on the v6 integrin. A, following influenza or sham infection, C57/Bl6
mice were weighed. Gray line, sham
 isotype control; gray dash, x31
 isotype control; black line, x31
 anti-v6 integrin; black dash, sham
 anti-v6
integrin. Data are represented asmean percentage change in bodyweight fromday 0, and error bars are S.E. B, 5-m-thick tissue sections from sham-infected
(panel i) and x31-infected (panel ii) mice treated with an isotype control antibody (1E6), or x31-infected mice (panel iii) treated with an anti-v6-blocking
antibody (6.3G9) were stained with an anti-influenza A antibody. Sections were visualized under a light microscope, and positive staining was identified in
influenza-infectedbutnot sham-infectedmice.C,hydroxyproline levelswere assessed in lungs 5days following influenza infection inC57BL/6mice (n8; x31,
50 HAU in saline i.n.) and compared with mock-infected (n 8; 50 l 0.9% saline i.n.) control mice. Mice pretreated with anti-v6 integrin blocking (n 8)
antibody had significantly reduced hydroxyproline levels comparedwithmice treatedwith an isotype control (n 8). Data are expressed as individual sample
valueswith the continuous line representing themean valueper group and error bars representing S.E. *,p	 0.05; ***,p	 0.001.D,homogenates of lungs from
mice euthanized on day 5were used to determine viral load via TCID50 assay. Data expressed as individual sample valueswith the continuous line representing
the mean value per group, and error bars representing S.E. E, 5-m-thick tissue sections from sham-infected (panels i–iv) and x31-infected (panels v–viii) mice
treated with an isotype control antibody (1E6) or x31-infected mice (panels ix–xii) treated with an anti-v6-blocking antibody (6.3G9) were stained with
anti-collagen I (panels i, v, and ix) anti-collagen III (panels ii, vi, and x), anti-collagen IV (panels iii, vii, and xi), and anti-collagen VI antibodies (panels iv, viii, and xii).
Sectionswere visualizedunder a lightmicroscope, andpositive stainingwas identified in regionsof lungwith evidenceof influenza infectionand inflammation
in mice treated with 1E6, but this was markedly reduced in animals treated with 6.3G9.
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integrin blocking antibody, compared with controls, this
appears unlikely.
Influenza virus enters epithelial cells via an endosomal path-
way, where replicating virus leads to the generation of dsRNA.
The viral dsRNA can activate endosomal TLR3 (23, 44) or the
cytosolic dsRNA sensors RIG-I and MDA-5 (23, 45, 46). To
distinguish between endosomal and cytosolic pathway involve-
ment, chloroquine was used to inhibit endosomal acidification.
In the presence of chloroquine, poly(I:C)-mediated activation
of TGF was abolished suggesting the involvement of TLR3
and not RIG-I orMDA-5. This was confirmed when H1N1 and
dsRNA-mediated TGF activation was inhibited using a dom-
inant negative TLR3 construct.
Activation of TGF via v6 integrins is dependent upon an
active cytoskeleton and traction forces within the cell being
transmitted to the intracellular 6 domain of the integrin (47).
This is mediated by activation of RhoA and Rho kinase, a small
monomeric GTPase involved in cellular contraction, in
response to GPCR agonist-induced v6-mediated activation
of TGF (15, 19). Recently, it has also been demonstrated that
agonists of TLR2 and TLR3 are able to activate RhoA via c-Src
in small airway epithelial cells (24). The data presented here
suggest that v6-dependent TGF activation may also occur
in a GPCR-independent manner via Rho kinase, the down-
stream effector of RhoA. However, a role for downstream
GPCR activation is possible. Recent data suggest that influenza
infection can increase RhoA activity in umbilical cord endothe-
lial cells (48), further supporting the hypothesis that influenza
infection is able to induce v6 integrin-mediated TGF acti-
vation via a cytoskeletal pathway.
In our system, administration of poly(I:C) or H1N1 resulted
in a 2-fold increase in TGF activity compared with controls
that is similar to levels of increasedv6-mediatedTGF activ-
ity that we have previously observed following GPCR stimula-
tion (15, 19). This increase in TGF activity in vitro is 25
pg/ml, and local tissue levels of thismagnitude are likely to be of
physiological importance, especially in the context of pre-exist-
ing lung disease.
Several mechanisms of TGF activation have been shown in
vitro, including extremes of temperature and pH and proteoly-
sis (7–9), whereas in vivo the primary mechanism of TGF
activation in the lung, at least in development, appears to
involve cell-surface integrins (12, 14). Influenza coat proteins
include NA, which is involved in the exit of viral progeny from
infected cells (20, 21). NA is a sialidase, and carbohydrate struc-
tures have been shown to confer latency to the large latent
complex of TGF (22, 49). Furthermore, previous studies have
described direct activation of latent TGF by both influenza
virus NA and bacterial NA in cell free systems (21). However,
we found no evidence of NA-mediated TGF activation in
human bronchial epithelial cells, suggesting that the sialidase
activity, at least of bacterial NA, is not sufficient to activate
TGF in cell-based assays. Although it is still possible that viral
NAcould be activatingTGFdirectly in vivo, these data suggest
that this is not the primary mechanism promoting epithelial
apoptosis or collagen deposition in the lung.
FIGURE 7.Collagen I, III, IV, andVI deposition throughout the lung following influenza infection and treatmentwith anti-v6 integrin antibody. The
5-m-thick tissue sections from sham-infected, x31-infected mice treated with an isotype control antibody (1E6) or x31-infected mice treated with an
anti-v6-blocking antibody (6.3G9) were stained with anti-collagen I, anti-collagen III, anti-collagen IV, and anti-collagen VI antibodies. Low power images
were visualized under a light microscope, and stitched images of whole lobe of lung are shown.
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FIGURE 8. Influenza A-induced collagen deposition requires Smad3 in vivo. A, SV129/BL6 mice (dashed black line) or Smad3/mice infected with A/FM/
1/47-MA (solid black line) did not show any change in their body weight 5 days following infection compared with sham-infected mice (dotted black line). B,
5-m-thick tissue sections from sham-infected (panel i), A/FM/1/47-MA-infected (panel ii) wild-typemice, or A/FM/1/47-MA-infected (panel iii) Smad3/mice
treated were stained with an anti-influenza A antibody. Sections were visualized under a light microscope, and positive staining was identified in influenza-
infected but not sham-infectedmice. C, hydroxyproline levels were assessed in lungs 5 days followingA/FM/1/47-MA infection in C57BL/6 SV129BL6mice and
comparedwith PBS control mice. Animals were grouped as follows: C57BL/6
 PBS (filled circle; n 8); C57BL/6 SV129/BL6
A/FM/1/47-MA (filled square; n
11); Smad3/mice
 A/FM/1/47-MA (filled triangle; n 8). Smad3/ had significantly lower collagen levels compared withWT C57BL/6mice infected with
A/FM/1/47-MA. Data are expressed as individual sample valueswith continuous line representing themean value per group and error bars representing S.E. **,
p	 0.01; ***, p	 0.001.D, homogenates of lungs frommice euthanized on day 5were used to determine the viral titer via TCID50 assay. Data are expressed as
individual sample values with continuous line representing the mean value per group and error bars representing S.E. E, 5-m-thick tissue sections from
sham-infectedmice (panels i–iv), wild-type A/FM/1/47-MA-infectedmice (panels v–viii), or A/FM/1/47-MA-infected Smad3/mice (panels ix–xii)were immu-
nostainedwithanti-collagen I (panels i, v,and ix), anti-collagen III (panels ii, vi,and x), anti-collagen IV (panels iii, vii,and xi), andanti-collagenVI antibodies (panels
iv, viii,and xii). Sectionswere visualizedunder a lightmicroscope, andpositive stainingwas identified in regionsof lungwithevidenceof influenza infectionand
inflammation in wild-type mice, but this was reduced in Smad3/mice.
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TGF is a highly pleiotropic molecule with diverse effects on
wound healing, immunology, and epithelial cell function. Its
role in the pathogenesis of viral infection remains unclear. Pro-
phylactically administered TGF was found to modify the
expression of both Th1 and Th2 cytokines, significantly
decreasing the population of CD4
 T cells, in the lungs of x31
influenza-infected mice. This was accompanied by impaired
pathogen clearance, increased viral load, and pathology (50).
Conversely, administration of plasmid DNA encoding active
TGF to mice 24 h following infection with H5N1 delayed
weight loss and prolonged survival while reducing viral load
(21). The diversity of these outcomes could relate to the strain
of virus used, the dose of TGF administered, or the delivery
system used to augment TGF levels. Enhanced morbidity has
been described in previous studies inhibiting global TGF
activity during influenza infection (21, 50). Using two different
murine H1N1 viruses, we found no effect of inhibiting TGF
signaling on morbidity or mortality. It is possible that Smad2 is
able to compensate for some of the antiviral effects of TGF
signaling in inflammatory cells, which may account for the
similar levels of influenza infection in both wild-type and
Smad3/mice.However, amajor strength of targeting epithe-
lial TGF activation by blocking the v6 integrin is that it
avoids any effects of inhibiting lymphocyte-associated TGF
which may have anti-inflammatory properties.
The increased lung collagen observed in x31-infected
C57Bl/6 mice was greater than observed in wild-type mice of a
mixed 129SV/C57Bl6 background infected with A/FM/1/47-
MA.Thismay be due to differences in the interferon response
betweenmice of different strains (51), which has been shown to
protect against virus-induced lung fibrosis (52). However,
inhibiting TGF signaling by administering 6.3G9, or using
Smad3/ animals, ameliorated the influenza-induced increase
in lung collagen levels. This suggests that this pathway is central
to influenza-induced collagen deposition.
Following influenza A infection, large increases in collagen I,
IV, andVI, and a smaller increase in collagen III, were found, all
of which were diminished by inhibiting TGF signaling. This is
consistent with the known effects of TGF on collagen I (53)
and collagen III (54). Collagen IV is the primary collagen of the
basement membrane (55), and the effects of disrupting TGF
signaling on collagen IV deposition are consistent with the
hypothesis that influenza promotes epithelial TGF activation.
Collagen VI is known to be up-regulated in pulmonary fibrosis
(56), but this is the first time its expression in the lung has been
shown to be regulated by TGF.
Increased TGF activation during influenza infection has
consistently been associated with enhanced epithelial cell apo-
ptosis (20, 57, 58). This is supported in vivo by our data showing
increased phosphorylated Smad2 and apoptosis 3 days post-
infection, and previouswork has found that peak viral titers also
occur at this time point (59). Influenza-induced epithelial apo-
ptosis may help limit infection of the lung in vivo by impeding
intracellular viral replication; however, enhanced epithelial
apoptosis is a well described pro-fibrotic pathway (60–63).
The role of influenza infection in the pathogenesis of pulmo-
nary fibrosis is unclear. It has been suggested that alveolar type
II cells from patients with idiopathic pulmonary fibrosis are
FIGURE9.Collagen I, III, IV, andVIdeposition throughout the lung following influenza infectionofSmad3/andwild-typemice.The5-m-thick tissue
sections from sham-infected mice, wild-type A/FM/1/47-MA-infected mice, or A/FM/1/47-MA-infected Smad3/mice were immunostained with anti-colla-
gen I, anti-collagen III, anti-collagen IV, and anti-collagen VI antibodies. Low power images were visualized under a light microscope, and stitched images of
whole lobe of lung are shown.
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more susceptible to viral infection with H1N1 influenza (64,
65). Clinical reports have suggested that H1N1 influenza infec-
tion can promote the development of pulmonary fibrosis with
radiological evidence of fibrosis as early as 1 week following
infection (65, 66). In animal models, influenza infection has led
to the development of lung fibrosis at 6 days following infection
(67) or as late as 14 days following infection (2). Our data sug-
gest that lung collagen can be deposited in the lung of virally
infectedmice as early as 5 days post-infection. Although we are
not proposing that influenza infection causes pulmonary fibro-
sis, it is evident that key mechanisms involved in the develop-
ment of fibrosis, including v6-mediated TGF activation (4,
68), epithelial apoptosis (25), and lung collagen deposition (69),
are triggered by influenza infection and may thus promote
fibrogenesis in an appropriately susceptible host. In conclusion,
the results described herein provide a novel mechanism
through which pulmonary infection with influenza virus can
result in the activation of TGF via a Smad3-, TLR3-, and v6
integrin-dependent pathway. This, in turn, induces epithelial
apoptosis and promotes fibrosis in anv6 integrin-dependent
manner.
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